Multiple Sclerosis Treatment Companies

December 2023Roche Holding AG, Presented positive Phase 3 data for Ocrevus® (ocrelizumab) in the prevention of disability progression in relapsing-remitting MS (RRMS), potentially offering a longer-term treatment option. Collaborated with patient advocacy groups and research institutions to advance MS research and improve patient care.

Novartis AG Announced the launch of Gilenya® (fingolimod) in new markets for RRMS treatment, expanding patient access to this oral medication. Focused on developing and acquiring innovative therapies for diverse forms of MS, including progressive MS.

Biogen Received FDA approval for Tecfidera® (dimethyl fumarate) for the treatment of early primary progressive MS (PPMS), offering a new option for managing this challenging form of the disease. Invested in research and development of novel therapies, including B-cell depleting agents and neuroprotective compounds for MS.

Sanofi Genzyme Announced the initiation of Phase 3 clinical trials for Aubagio® (teriflunomide) in combination with pegylated interferon beta-1a for RRMS, aiming to enhance treatment efficacy. Collaborated with academic institutions to explore the potential of gene therapy and other innovative approaches for MS treatment.

• Teva Pharmaceuticals


• Bayer Healthcare


• Biogen Idec


• Pfizer Inc.


• Merck


• Novartis


• Janssen Pharmaceuticals Inc


• Bristol-Myers Squibb Company


• AbbVie